EQUITY (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common stock, shares outstanding	8,335,606	8,296,256
Capital stock shares authorized	155,000,000
Capital stock par value	$ 0.0001
Common stock shares authorized	150,000,000	150,000,000
Stock option description	98,838   options are subject to a three-year vesting period, with one-third of such awards vesting each year and 55,670 options with performance conditions, mainly related to clinical activities
Fair value assumptions, dividend rate	0.00%
Fair value assumptions, volatility rate minimum	127.43%
Fair value assumptions, volatility rate maximum	130.93%
Fair value assumptions, risk free interest rate minimum	1.79%
Fair value assumptions, risk free interest rate maximum	2.88%
Three Year Vesting Period [Member]
Class of Stock [Line Items]
Stock option grants in period	98,838
Performance Conditions [Member]
Class of Stock [Line Items]
Stock option grants in period	55,670
Minimum [Member]
Class of Stock [Line Items]
Fair value assumptions, expected term	5 years 1 month 15 days
Maximum [Member]
Class of Stock [Line Items]
Fair value assumptions, expected term	6 years 6 months
Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Stock option grants in period	154,508
Vesting period	3 years
Fair value stock option price	$ 360,356
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Class of Stock [Line Items]
Weighted average exercise price	$ 2.61
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Class of Stock [Line Items]
Weighted average exercise price	$ 2.97
Restricted Stock [Member]
Class of Stock [Line Items]
Stock granted	13,987
Stock vesting period	3 years
Fair value of restricted shares	$ 25,736
Warrant [Member]
Class of Stock [Line Items]
Purchase of warrants	1,793,815
Preferred Stock Blank Check [Member]
Class of Stock [Line Items]
Preferred stock shares authorized	5,000,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Common stock, shares outstanding	1,718
Conversion of series C convertible preferred stock to common shares, shares	2,280